UBE3B promotes breast cancer progression by antagonizing HIF-2α degradation

Area of Science:

• Molecular Biology
• Oncology
• Biochemistry

Background:

• Mutations in E3 ubiquitin ligase UBE3B are associated with Kaufman Oculocerebrofacial Syndrome (KOS).
• Emerging evidence suggests a significant role for UBE3B in cancer development.
• The specific function and mechanism of UBE3B in cancer remain largely unknown.

Purpose of the Study:

• To elucidate the role of UBE3B in cancer.
• To investigate the mechanism by which UBE3B influences cancer progression.
• To identify UBE3B as a potential therapeutic target in cancer treatment.

Main Methods:

• Investigated the interaction between UBE3B and hypoxia-inducible factor 2α (HIF-2α).
• Assessed the effect of UBE3B depletion on breast cancer cell proliferation, migration, and invasion in vitro.
• Evaluated the impact of UBE3B on tumor growth and metastasis in vivo.
• Identified key ubiquitination sites on HIF-2α using mutational analysis.

Main Results:

• UBE3B functions as an E3 ligase for HIF-2α, promoting its K63-linked polyubiquitination.
• UBE3B inhibits HIF-2α degradation mediated by the VHL E3 ligase complex.
• Depletion of UBE3B suppressed breast cancer cell proliferation, migration, invasion, tumor growth, and lung metastasis.
• Specific lysine residues (K394, K497, K503) on HIF-2α were identified as critical for UBE3B-mediated regulation.
• UBE3B and HIF-2α protein levels were found to be upregulated and positively correlated in breast cancer tissues.

Conclusions:

• UBE3B plays a critical role in regulating HIF-2α stability and function.
• UBE3B promotes breast cancer progression and metastasis through HIF-2α stabilization.
• The UBE3B-HIF-2α axis represents a potential therapeutic target for breast cancer treatment.